Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern

13 Mar 2022

Abstract excerpt

The prolonged duration of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has resulted in the continuous emergence of variants of concern (VOC, e.g., Omicron) and variants of interest (VOI, e.g., Lambda). These variants have challenged the protective efficacy of current COVID-19 vaccines, thus calling for the development of novel therapeutics against SARS-CoV-2 and its VOCs. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to CRISPR and Genetic Engineering
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35337003
DOI: 10.3390/v14030597

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of ConcernPMID 35337003Read ↗

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigenSemantic proximity Read ↗

Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike proteinSemantic proximity Read ↗

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptidesSemantic proximity Read ↗

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccinesSemantic proximity Read ↗

Targeting an evolutionarily conserved “E-L-L” motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2Semantic proximity Read ↗

Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 SubunitSemantic proximity Read ↗

Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionSemantic proximity Read ↗

Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its VariantsSemantic proximity Read ↗

A Potential Novel COVID-19 Vaccine With RBD-HR1/HR2 Hexamer StructureSemantic proximity Read ↗

A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potentialSemantic proximity Read ↗

Recombinant protein HR212 targeting heptad repeat 2 domain in spike protein S2 subunit elicits broad‐spectrum neutralizing antibodies against SARS‐CoV‐2 and its variantsSemantic proximity Read ↗

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.